Article ID | Journal | Published Year | Pages | File Type |
---|---|---|---|---|
599069 | Colloids and Surfaces B: Biointerfaces | 2016 | 8 Pages |
•Deformable liposomes coated with chitosan (DL-CS) were developed.•DL-CS could prolong pre-corneal retention and improve transcorneal penetration.•Edge activator, Solutol HS-15, could potentiate the flexibility and penetrability.•DL-CS could be a promising ocular drug delivery system.
In this study, novel chitosan-coated deformable liposomes (DL-CS) were proposed as an ocular drug delivery system to prolong pre-corneal retention, and improve transcorneal penetration and absorption. Flurbiprofen-loaded deformable liposomes (FP-DL) were prepared by a modified ethanol injection method and then coated with chitosan. Both DL and DL-CS exhibited a homogeneous particle size distribution, high encapsulation efficiency and good stability. After coating with 0.1% CS, the zeta potential was shifted from negative to positive. The apparent permeability coefficient of FP-DL-0.1% CS evaluated using isolated rabbit corneas was 1.29-, 1.95- and 4.59- fold greater than that of uncoated FP-DL, conventional liposomes and FP solution (P < 0.01), respectively. The in vivo pre-corneal retention time and elimination dynamics were assessed using gamma scintigraphy technology. The area under the remaining activity-time of FP-DL-0.1% CS was prolonged 2.84- and 1.53-fold compared with that of the FP solution and FP-DL groups, respectively. Moreover, the ocular irritation test in vivo revealed that DL-0.1% CS produced no ocular damage or abnormal clinical signs. These results indicate that DL-CS appears to be a novel ophthalmic drug delivery strategy with the potential to overcome the limitations of conventional eye drops.
Graphical abstractFigure optionsDownload full-size imageDownload as PowerPoint slide